Is there a generic for Crestor?

Yes — 20 approved generic versions of Crestor (rosuvastatin) are tracked in our index. Generic substitution is typically automatic at the pharmacy unless the prescriber writes "dispense as written."

How much cheaper is generic rosuvastatin?

Generic small-molecule drugs typically launch at 60-80% discount to the originator. After multiple manufacturers enter the market (12-24 months post-cliff), prices drop further to 85-95% below originator. Your insurance copay may not reflect the full savings — check the cash price too.

Are generics as effective as the brand?

For small-molecule drugs: yes. Generics are required to demonstrate bioequivalence — identical active ingredient, same dose, same route, same indication. Pharmacokinetic equivalence within tight bounds (±20% AUC + Cmax). Most patients can switch without clinical effect.

When did Crestor go generic?

Generic rosuvastatin entered the US market when the originator's exclusivity expired. See the patent timeline below for specific dates.

Last reviewed 2026-06-10 · How we verify

Crestor generic

Complete generic competition for Crestor (rosuvastatin): 20 approved generics across manufacturers, 0 filed under FDA review. Sourced from FDA Orange Book + USPTO.

20 approved generics Patents expired

About Crestor

Crestor (rosuvastatin) — originally marketed by AstraZeneca. Class: HMG-CoA reductase inhibitor (statin). First approved 2003-01-01.

Approved generic versions (20)

Generic	Manufacturer	Phase	First approval
ROSUVASTATIN		marketed	2003-01-01
Rosuvastatin Oral Tablet	Washington State University	marketed
Rosuvastatin-ranitidine	Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec	marketed
Rosuvastatin plus clopidogrel	Federal University of São Paulo	marketed
Rosuvastatin and fenofibrate	Gachon University Gil Medical Center	marketed
rosuvastatin 7 days	Radboud University Medical Center	marketed
Rosuvastatin; improvement of lipid profile	AstraZeneca	marketed
Rosuvastatin (Crestor)	Minneapolis Heart Institute Foundation	marketed
Rosuvastatin alone	Gachon University Gil Medical Center	marketed
Rosuvastatin-omeprazole	Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec	marketed
Rosuvastatin-esomeprazole	Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec	marketed
Rosuvastatin(Cresnon®)	Dong-A ST Co., Ltd.	marketed
rosuvastatin and clopidogrel	The Third Affiliated Hospital of Guangzhou Medical University	marketed
Rosuvastatin and Ezetimibe	Hanmi Pharmaceutical Company Limited	marketed
Rosuvastatin 20mg	AstraZeneca	marketed
Rosuvastatin plus ticagrelor	Federal University of São Paulo	marketed
Rosuvastatin calcium 40mg	Seung-Jung Park	marketed
Rosuvastatin or atorvastatin or simvastatin and clopidogrel	AstraZeneca	marketed
Rosuvastatin and Ezetimibe morning or evening administration	Collegium Medicum w Bydgoszczy	marketed
Rosuvastatin-pantoprazole	Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec	marketed

Originator patent timeline

Active patents (0)

No active patents tracked.

Expired patents (0)

No expired patents tracked.

How small-molecule generic approval works

Generic versions of small-molecule drugs are approved by the FDA via the Abbreviated New Drug Application (ANDA) pathway under the Hatch-Waxman Act of 1984. Sponsors must demonstrate bioequivalence (pharmacokinetic equivalence within tight bounds) and identical chemical composition — no clinical trials in patients are required. Approval typically takes 18-24 months.

This is different from biosimilars for biologic drugs, which use the more complex 351(k) BLA pathway and typically achieve smaller (15-35%) discounts vs the originator. Small-molecule generics typically launch at 60-80% discount, dropping to 85-95% within 2 years.

Subscribe to generic updates

Crestor full drug profile
Biosimilar tracker (for biologic drugs)
Patent cliff tracker
Biosimilar vs generic — what's the difference?

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing